The Journal of Pediatrics
Volume 151, Issue 1 , Pages 34-42.e1 , July 2007

Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing

  • Eric A.F. Simoes, MB, BS, DCH, MD

      Affiliations

    • Department of Pediatric Infectious Diseases, University Of Colorado School Of Medicine and The Children’s Hospital, Denver, CO
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • Corresponding Author InformationReprint requests: Eric A. F. Simoes, MD, DCH, The Children’s Hospital, 1056 E 19th Ave, B070, Denver, CO 80218.
    • ,
  • Jessie R. Groothuis, MD

      Affiliations

    • Abbott Laboratories, Inc, Chicago, IL
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • Dr Groothuis currently is Vice President, Medical and Scientific Affairs and Head, Infectious Diseases and Vaccines, MedImmune, Inc.
    • ,
  • Xavier Carbonell-Estrany, MD, PhD

      Affiliations

    • Neonatology Service, Hospital Clinic, Institute and Clinic of Gynecology, Obstetrics and Neonatology, Barcelona, Spain
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Christian H.L. Rieger, MD

      Affiliations

    • Department of Pediatrics, St Josef Hospital, Ruhr University, Bochum, Germany
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Ian Mitchell, MA, MB, ChB

      Affiliations

    • Institute of Maternal and Child Health, University of Calgary, Calgary, Alberta, Canada
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Linda M. Fredrick, MS

      Affiliations

    • Abbott Laboratories, Abbott Park, IL
    • Linda Fredrick currently is an employee of Abbott Laboratories.
    • ,
  • Jan L.L. Kimpen, MD, PhD

      Affiliations

    • Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center, Utrecht, The Netherlands.
    • Drs Simoes, Groothuis, Carbonell-Estrany, Rieger, Mitchell and Kimpen are members of the Steering Committee of the Palivizumab Long-Term Respiratory Outcomes Study and are consultants for Abbott Laboratories.
    • ,
  • Palivizumab Long-Term Respiratory Outcomes Study Group

      Affiliations

    • The members of the Palivizumab Long-Term Respiratory Outcomes Study Group are listed in an appendix, available at www.jpeds.com.

Received 14 April 2006 ,Revised 28 December 2006 ,Accepted 8 February 2007.

  • Image Result

    A, Comparison of respiratory outcomes between the palivizumab-treated (treated) and untreated groups. Results are expressed as frequency of respiratory outcomes or incidence rates per 100 child-years

    A, Comparison of respiratory outcomes between the palivizumab-treated (treated) and untreated groups. Results are expressed as frequency of respiratory outcomes or incidence rates per 100 child-years of observation for respiratory outcomes in univariate analyses. The results are graphically represented as point estimates of the RR and 95% CIs. B, Kaplan-Meier plot showing time to the third episode of recurrent wheezing in palivizumab-treated versus combined untreated (P = .001) and palivizumab-treated versus untreated and not hospitalized for RSV LRTI (P = .013) cohorts. C, Kaplan-Meier plot showing time to third episode of physician-diagnosed recurrent wheezing in palivizumab-treated (solid gray line) versus combined untreated (solid black line) (P = .009) and treated versus untreated and not hospitalized for RSV LRTI (dashed line) (P = .020) cohorts.

 This study was funded by grants from Abbott Laboratories to the individual investigators. The study sponsors collaborated on study design, managed data collection, and performed data analysis.

PII: S0022-3476(07)00161-8

doi: 10.1016/j.jpeds.2007.02.032

The Journal of Pediatrics
Volume 151, Issue 1 , Pages 34-42.e1 , July 2007

Article Tools

* Image Usage & Resolution